Uykusuzluk ve majör depresif bozukluk arasında-ki bağlantı: Bir tavuk ve yumurta durumu mudur?
The relationship between insomnia and major depressive disorder: a chicken and egg situation?
Major Depressive Disorder (MDD) is highly prevalent, severely debilitating, and often recurrent. The majority of individuals with MDD experience sleep disturbances. MDD is also over-represented in populations with a variety of sleep disorders. Although sleep disturbances are typical features of MDD, such symptoms sometimes appear prior to an episode of MDD. The bidirectional association between sleep disturbance, especially insomnia and MDD, increases the difficulty of differentiating cause-and-effect relationship between them. Longitudinal studies have consistently identified insomnia as a risk factor for the development of a new-onset or recurrent MDD, and this association has been identified in young, middle-aged, and even older adults. Researches have also observed that the combination of insomnia and depression influences the trajectory of MDD, increasing episode severity and duration, as well as relapse rates. Fortunately, recent studies have demonstrated that both pharmacological and non-pharmacological interventions for insomnia may favourably reduce and possibly prevent MDD. Together, these findings suggest that sleep-related symptoms that are present before, during, and/or after a major depressive episode are potentially modifiable factors that may play an important role in achieving and maintaining remission of depression.
issue, since the incidence of depression is expected to increase as a result of prolonged life expectancy and social and demographic changes (5).
Definitions of Specific Terms used in Evaluating and

Treating Major Depressive Disorder Clinically
Response
The American College of Neuropsychopharmacology (ACNP) Task Force agreed with the widely held concept that response represents a clinically meaningful degree of reduction in depressive symptoms, and restated the commonly accepted criterion of a ≥50% reduction in baseline severity, assessed by a symptom severity rating scale (6) .
Full remission
Similarly, the recommendation of the ACNP Task Force is to use a score of ≤7 or ≤5 on the HAMD-17 scale as criteria for full remission (6) . Full remission is obtained where clinical improvement is such that the patient becomes almost asymptomatic.
Partial remission
Partial remission is defined as a period of time with some improvement of symptoms, but not of enough magnitude as to achieve full remission, and with the persistence of some residual symptoms. This state corresponds to a score of 8 to 15 on the HAMD-17 (7).
Recovery
Recovery from depression was defined as a period of at least 2 months during which there were no significant symptoms of depression, which was defined operationally as 8 consecutive HAMD-17 scores of 7 or less within 6 months of beginning medical treatment and subsequent confirmation of the absence of major depression by diagnostic re-evaluation (8) .
Relapse
Relapse was viewed as a return of the index major depressive episode (MDE) following the onset of full or partial remission but before fulfilling the criteria for recovery. So, relapse can be defined as the re-appearance or aggravation of symptoms to score 18 or more on the HAMD-17 scale for at least 2 consecutive weeks in the partial or full remission period (6) .
Recurrence
Recurrence referred to the development of a new MDE following the recovery. In other words, a new MDE which fully met diagnostic criteria must emerge during the recovery period for the term of recurrence according to The ACNP Task Force (6) .
The Significance of Full Remission and The Role of
Residual Symptoms
In recent years, the ACNP Task Force has established remission as the goal of treatment for patients with MDD (6) . The most widely used criterion for remission is a Hamilton Rating Scale for Depression (HAMD-17) score of ≤7, which corresponds to a HAMD-7 score of ≤3 (9).
However, the recommendation of the ACNP Task Force is to use a score of ≤7 or ≤5 on the HAMD-17 scale as criteria for remission (6) . Furthermore, although the goal of treating MDD is to achieve full remission, it is common for many patients to continue suffering from residual symptoms after they respond to treatment (10) 
The Importance of Sleep Disturbance as a Residual Symptom
Whether all previously mentioned diagnostic depressive symptoms weigh equally with regards to their adverse impact on functioning, morbidity, mortality, and treatment outcome or whether some symptoms are more relevant than others remain, as of yet, undetermined.
However, several studies published to date suggest that sleep disturbance may represent such a symptom that weighs more heavily with regards to its adverse impact on a number of outcomes (12) . For instance, complaints of poor sleep are reported in up to 90% of people with diagnosed depression (13, 14) . Among the residual symptoms, disturbed sleep is also the most prevalent (15). Of all sleep-related complaints, insomnia (and resultant daytime sleepiness) is the most frequent (5) . In a recent study the patients in remission after completing at least 20 weeks of therapy, 22%, 26%, and 17% still suffered from initial insomnia, middle insomnia, and terminal insomnia, respectively (17) . More than 40% of patients reported symptoms of fatigue and sleepiness/sedation even they were inpartial or full remission (18) .
The Consequences of Insomnia in Terms of Major Depressive Disorder in Presently Healthy Individuals
Insomnia and depression are also bi-directionally related (19) . So, insomnia is a risk factor for developing depression and residual insomnia symptoms after a major depressive episode increase the risk of relapse and The association between insomnia and major depressive relapse or recurrence has also been reported in more recent studies (32, 33, 34) . Armitage stated that persistent sleep problems, insomnia specifically, elevate the risk of relapse and recurrence, as well as the need for augmenting medications (32) . Additionally, Ohayon and Roth showed that insomnia appeared before (>40%) or in the same time (>22%) than mood disorder symptoms in most cases of mood disorders (33) . So, chronic insomnia can be a residual symptom of a previous mood disorder and put these subjects to a higher risk of relapse. Subjective sleep problems, including insomnia, were also found to be predictors of early recurrence in a study of "remitted" patients maintained on an SSRI and psychotherapy (34) .
Very recently, we have assessed the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers (35) . Majority of the participants had subjective sleep disturbance, insomnia prior to relapse or recurrence. 
